Misoprostol in Spontaneous Abortion: Why Nurses Must Lead the Conversation

The pharmacologic management of spontaneous abortion with misoprostol is a clinically essential, evidence-based intervention. However, the conflation of "spontaneous abortion" and "medically induced abortion" in political discourse, lay media, and emerging legislation threatens access to this medication for persons experiencing pregnancy loss. Failure to correct this conflation risks regulatory and prescribing barriers that could result in serious maternal harm, including retained products of conception leading to hemorrhage and sepsis. Nurses, positioned at the front line of reproductive and perinatal health, are professionally obligated to lead clear, evidence-based communication that distinguishes these two unique clinical indications. Abortion bans may increase pregnancy-associated deaths and second-trimester sepsis rates among patients experiencing pregnancy loss. Nurses must engage in clinical advocacy, patient education, and policy dialogue to safeguard pharmaceutical access and protect maternal health outcomes.